ICD-10-CM Code T45.1X5S

Adverse effect of antineoplastic and immunosuppressive drugs, sequela

Version 2020 Replaced Code Billable Code Unacceptable Principal Diagnosis POA Exempt

Valid for Submission

T45.1X5S is a billable code used to specify a medical diagnosis of adverse effect of antineoplastic and immunosuppressive drugs, sequela. The code is valid for the year 2020 for the submission of HIPAA-covered transactions. The ICD-10-CM code T45.1X5S might also be used to specify conditions or terms like accelerated rheumatoid nodulosis, accelerated rheumatoid nodulosis due to methotrexate, aclarubicin adverse reaction, acral erythema, acral erythema due to cytotoxic therapy, acute myeloid leukemia and myelodysplastic syndrome related to alkylating agent, etc The code is exempt from present on admission (POA) reporting for inpatient admissions to general acute care hospitals.

The code T45.1X5S describes a circumstance which influences the patient's health status but not a current illness or injury. The code is unacceptable as a principal diagnosis.

ICD-10:T45.1X5S
Short Description:Adverse effect of antineopl and immunosup drugs, sequela
Long Description:Adverse effect of antineoplastic and immunosuppressive drugs, sequela

Replaced Code

This code was replaced in the 2020 ICD-10 code set with the code(s) listed below. The National Center for Health Statistics (NCHS) has published an update to the ICD-10-CM diagnosis codes which became effective October 1, 2019. This code was replaced for the FY 2020 (October 1, 2019 - September 30, 2020).

  • K59.03 - Drug induced constipation

Code Edits

The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10 Code Edits are applicable to this code:

  • Unacceptable principal diagnosis - There are selected codes that describe a circumstance which influences an individual’s health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.

Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

  • Accelerated rheumatoid nodulosis
  • Accelerated rheumatoid nodulosis due to methotrexate
  • Aclarubicin adverse reaction
  • Acral erythema
  • Acral erythema due to cytotoxic therapy
  • Acute myeloid leukemia and myelodysplastic syndrome related to alkylating agent
  • Acute myeloid leukemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor
  • Acute promyelocytic leukemia, FAB M3
  • Adverse reaction to antineoplastic antibiotics
  • Adverse reaction to drug or medicament administered by infusion
  • Adverse reaction to drug or medicament administered by infusion
  • Adverse reaction to rituximab administered by infusion
  • Adverse reaction to trastuzumab administered by infusion
  • Aldesleukin adverse reaction
  • Alkylating drug adverse reaction
  • Amifostine adverse reaction
  • Amsacrine adverse reaction
  • Antimetabolite adverse reaction
  • Antineoplastic adverse reaction
  • Aplastic anemia caused by antineoplastic agent
  • Aplastic anemia due to drugs
  • Azathioprine adverse reaction
  • Azoospermia
  • Azoospermia caused by chemotherapy
  • Bleomycin adverse reaction
  • Busulfan adverse reaction
  • Carboplatin adverse reaction
  • Carmustine adverse reaction
  • Cellular atypia due to antineoplastic agent
  • Chlorambucil adverse reaction
  • Chlormethine adverse reaction
  • Chronic cyclosporin A nephrotoxicity
  • Chronic drug-induced renal disease
  • Chronic drug-induced renal disease
  • Chronic drug-induced renal disease
  • Chronic painful polyneuropathy following chemotherapy
  • Cirrhosis of liver caused by methotrexate
  • Cisplatin adverse reaction
  • Cis-platinum nephropathy
  • Complication of chemotherapy
  • Crisantaspase adverse reaction
  • Cyclophosphamide adverse reaction
  • Cyclosporin adverse reaction
  • Cytarabine adverse reaction
  • Cytotoxic antibiotic adverse reaction
  • Dacarbazine adverse reaction
  • Dactinomycin adverse reaction
  • Dermatosis resulting from immunosuppressive therapy
  • Differentiation syndrome due to and following chemotherapy co-occurrent with acute promyelocytic leukemia
  • Dimethyl sulfoxide adverse reaction
  • Doxorubicin adverse reaction
  • Drug-induced cirrhosis of liver
  • Drug-induced immunodeficiency
  • Epirubicin adverse reaction
  • Esophagitis due to chemotherapy
  • Estramustine adverse reaction
  • Ethoglucid adverse reaction
  • Etoposide adverse reaction
  • Fludarabine adverse reaction
  • Fluorouracil adverse reaction
  • Gonad regulating hormone adverse reaction
  • Gonad regulating hormone adverse reaction
  • Gonad regulating hormone adverse reaction
  • Goserelin adverse reaction
  • Hydroxycarbamide adverse reaction
  • Idarubicin adverse reaction
  • Ifosfamide adverse reaction
  • Immunodeficiency secondary to chemotherapy
  • Immunosuppressant adverse reaction
  • Leuprorelin adverse reaction
  • Lomustine adverse reaction
  • Lymphoproliferative disorder caused by methotrexate
  • Malignant neoplasm after immunosuppressive therapy
  • Melphalan adverse reaction
  • Mercaptopurine adverse reaction
  • Methotrexate adverse reaction
  • Methotrexate poisoning
  • Methotrexate skin ulceration
  • Methyl CCNU nephropathy
  • Mitobronitol adverse reaction
  • Mitomycin adverse reaction
  • Mitoxantrone adverse reaction
  • Mucositis following chemotherapy
  • Mucositis following therapy
  • Nephropathy induced by cyclosporine
  • Nephropathy induced by tacrolimus
  • Neurological pain disorder
  • Neurotoxicity
  • Neurotoxicity
  • Neurotoxicity
  • Neurotoxicity
  • Neurotoxicity
  • Neurotoxicity due to L-asparaginase
  • Neurotoxicity due to methotrexate
  • Neurotoxicity due to procarbazine
  • Neurotoxicity due to vinblastine
  • Neurotoxicity due to vincristine
  • Nitrogen mustard derivative adverse reaction
  • Nitrosurea adverse reaction
  • Oral ulcerative mucositis due to antineoplastic therapy
  • Paclitaxel adverse reaction
  • Pancytopenia caused by medication
  • Pancytopenia due to antineoplastic chemotherapy
  • Pentostatin adverse reaction
  • Peripheral neuropathy due to and following chemotherapy
  • Piperazine adverse reaction
  • Plicamycin adverse reaction
  • Poisoning by L-asparaginase
  • Procarbazine adverse reaction
  • Procarbazine poisoning
  • Razoxane adverse reaction
  • Retinoid adverse reaction
  • Rheumatoid nodulosis
  • Secondary aplastic anemia
  • Stomatitis due to cytotoxic therapy
  • Stomatitis medicamentosa
  • Stomatitis medicamentosa
  • Therapy related acute myeloid leukemia and myelodysplastic syndrome
  • Therapy related acute myeloid leukemia and myelodysplastic syndrome
  • Therapy related acute myeloid leukemia and myelodysplastic syndrome
  • Therapy related acute myeloid leukemia due to and following administration of antineoplastic agent
  • Thioguanine adverse reaction
  • Thiotepa adverse reaction
  • Thrombophilia due to antineoplastic agent therapy
  • Thrombophilia due to drug therapy
  • Treosulfan adverse reaction
  • Triazene antineoplastic adverse reaction
  • Triptorelin adverse reaction
  • Ulcerative stomatitis
  • Vinblastine adverse reaction
  • Vinblastine poisoning
  • Vinca alkaloid adverse reaction
  • Vincristine adverse reaction
  • Vincristine poisoning
  • Vindesine adverse reaction

Diagnostic Related Groups

The ICD-10 code T45.1X5S is grouped in the following groups for version MS-DRG V37.0 What are Diagnostic Related Groups?
The Diagnostic Related Groups (DRGs) are a patient classification scheme which provides a means of relating the type of patients a hospital treats. The DRGs divides all possible principal diagnoses into mutually exclusive principal diagnosis areas referred to as Major Diagnostic Categories (MDC).
applicable from 10/01/2019 through 09/30/2020.

  • 922 - OTHER INJURY, POISONING AND TOXIC EFFECT DIAGNOSES WITH MCC
  • 923 - OTHER INJURY, POISONING AND TOXIC EFFECT DIAGNOSES WITHOUT MCC

Present on Admission (POA)

T45.1X5S is exempt from POA reporting - The Present on Admission (POA) indicator is used for diagnosis codes included in claims involving inpatient admissions to general acute care hospitals. POA indicators must be reported to CMS on each claim to facilitate the grouping of diagnoses codes into the proper Diagnostic Related Groups (DRG). CMS publishes a listing of specific diagnosis codes that are exempt from the POA reporting requirement. Review other POA exempt codes here .

CMS POA Indicator Options and Definitions
POA Indicator CodePOA Reason for CodeCMS will pay the CC/MCC DRG?
YDiagnosis was present at time of inpatient admission.YES
NDiagnosis was not present at time of inpatient admission.NO
UDocumentation insufficient to determine if the condition was present at the time of inpatient admission.NO
WClinically undetermined - unable to clinically determine whether the condition was present at the time of inpatient admission.YES
1Unreported/Not used - Exempt from POA reporting. NO

Convert T45.1X5S to ICD-9

  • 909.5 - Lte efct advrs efct drug (Combination Flag)
  • E933.1 - Adv eff antineoplastic (Combination Flag)

Code Classification

  • Injury, poisoning and certain other consequences of external causes (S00–T98)
    • Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances (T36-T50)
      • Primarily systemic and hematological agents, NEC (T45)

Code History

  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016
    (First year ICD-10-CM implemented into the HIPAA code set)
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020

Information for Patients


Drug Reactions

Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions.

One problem is interactions, which may occur between

  • Two drugs, such as aspirin and blood thinners
  • Drugs and food, such as statins and grapefruit
  • Drugs and supplements, such as ginkgo and blood thinners
  • Drugs and diseases, such as aspirin and peptic ulcers

Interactions can change the actions of one or both drugs. The drugs might not work, or you could get side effects.

Side effects are unwanted effects caused by the drugs. Most are mild, such as a stomach aches or drowsiness, and go away after you stop taking the drug. Others can be more serious.

Drug allergies are another type of reaction. They can be mild or life-threatening. Skin reactions, such as hives and rashes, are the most common type. Anaphylaxis, a serious allergic reaction, is more rare.

When you start a new prescription or over-the-counter medication, make sure you understand how to take it correctly. Know which other medications and foods you need to avoid. Ask your health care provider or pharmacist if you have questions.


[Learn More]